Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Corcept Therapeutics (NASDAQ:CORT) had its price target boosted by investment analysts at Canaccord Genuity Group from $99.00 to $100.00 in a report released on Friday, MarketBeat reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target indicates a potential upside of 127.38% from the stock’s previous close.

Several other equities research analysts also recently commented on the stock. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research note on Wednesday, December 31st. Wall Street Zen cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. UBS Group assumed coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target on the stock. Finally, Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research report on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Corcept Therapeutics has a consensus rating of “Hold” and a consensus target price of $83.50.

Corcept Therapeutics Trading Up 6.5%

NASDAQ CORT opened at $43.98 on Friday. Corcept Therapeutics has a 12 month low of $32.99 and a 12 month high of $117.33. The stock has a 50-day simple moving average of $65.24 and a 200 day simple moving average of $71.12. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $4.63 billion, a PE ratio of 49.98 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.02). The company had revenue of $207.64 million for the quarter, compared to analyst estimates of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.Corcept Therapeutics’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.41 earnings per share. Research analysts forecast that Corcept Therapeutics will post 1.36 EPS for the current year.

Insider Buying and Selling at Corcept Therapeutics

In related news, CEO Joseph K. Belanoff sold 40,000 shares of Corcept Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.77, for a total value of $3,190,800.00. Following the sale, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.53, for a total value of $397,650.00. Following the sale, the insider owned 10,277 shares in the company, valued at $817,329.81. The trade was a 32.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 194,500 shares of company stock valued at $14,186,410. Corporate insiders own 20.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Assetmark Inc. boosted its holdings in shares of Corcept Therapeutics by 26.8% in the 4th quarter. Assetmark Inc. now owns 82,098 shares of the biotechnology company’s stock valued at $2,857,000 after buying an additional 17,372 shares during the last quarter. State of Alaska Department of Revenue raised its position in Corcept Therapeutics by 19.4% during the fourth quarter. State of Alaska Department of Revenue now owns 56,312 shares of the biotechnology company’s stock worth $1,958,000 after acquiring an additional 9,147 shares in the last quarter. Stanley Laman Group Ltd. lifted its stake in Corcept Therapeutics by 36.1% in the fourth quarter. Stanley Laman Group Ltd. now owns 33,311 shares of the biotechnology company’s stock valued at $1,159,000 after acquiring an additional 8,828 shares during the last quarter. Triad Wealth Partners LLC acquired a new stake in Corcept Therapeutics in the fourth quarter valued at $315,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Corcept Therapeutics by 16.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 20,521 shares of the biotechnology company’s stock valued at $714,000 after acquiring an additional 2,877 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA met its overall survival primary endpoint in platinum‑resistant ovarian cancer — a clear clinical success that materially improves relacorilant’s value thesis and is the main driver of the move. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
• Positive Sentiment: Multiple trade and analyst outlets reported the OS win, reinforcing market confidence that the drug could drive future revenue and partnership interest. CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
• Positive Sentiment: Wall‑street coverage (e.g., Reuters) flagged the late‑stage success, increasing visibility with institutional investors and media, which can amplify buying interest. Corcept’s cancer drug meets main goal in late-stage trial
• Positive Sentiment: Analyst optimism picked up: Canaccord raised its price target to $100 and maintained a buy rating, signaling upside potential versus the current price and likely supporting additional demand. CORT Corcept Therapeutics price target raised by Canaccord
• Neutral Sentiment: Options flow shows elevated activity: about 4,870 put contracts were purchased (≈78% above the typical daily put volume), indicating some investors are hedging or speculating on near‑term volatility rather than a clear directional consensus. (No external link)
• Negative Sentiment: Regulatory and legal overhangs remain — shareholder law firms (Hagens Berman and Pomerantz) launched investigations tied to the company’s prior FDA complete response letter for relacorilant in Cushing’s syndrome and the sharp December sell‑off, which could lead to litigation costs or disclosure risk. CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
• Negative Sentiment: Remember the December FDA complete response letter for relacorilant (Cushing’s syndrome) that previously drove a large share price drop — regulatory uncertainty remains a material risk even after the oncology win. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated – CORT

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.